Khorana score | ||||
Risk factor | Points | |||
Site of primary tumor | ||||
Very high risk (stomach, pancreas) | 2 | |||
High risk (lung, lymphoma, gynecologic, bladder, testicular) | 1 | |||
All other sites | 0 | |||
Pre-chemotherapy platelet count ≥350,000/microL | 1 | |||
Hemoglobin level <10 g/dL or use of ESAs | 1 | |||
Pre-chemotherapy WBC >11,000/microL | 1 | |||
BMI ≥35 kg/m2 | 1 | |||
Incidence of VTE based on Khorana score | ||||
Khorana score points | Derivation cohort[1] VTE risk after 2.5 months | Validation cohort[1] VTE risk after 2.5 months | Independent cohort[2] VTE risk after 6 months | Patients in phase I trials[3] VTE risk after 2 months |
0 (low) | 0.8% | 0.3% | 1.5% | 1.5% |
1 to 2 (intermediate) | 1.8% | 2% | 3.8% (1 point); 9.6% (2 points) | 4.8% |
≥3 (high) | 7.1% | 6.7% | 17.7% | 12.9% |
Do you want to add Medilib to your home screen?